JP3256291B2 - Ｎ−アルキル−３−フェニル−３−（２−アルキルチオフェノキシ）プロピルアミン類 - Google Patents

Ｎ−アルキル−３−フェニル−３−（２−アルキルチオフェノキシ）プロピルアミン類

Info

Publication number
JP3256291B2
JP3256291B2 JP25632792A JP25632792A JP3256291B2 JP 3256291 B2 JP3256291 B2 JP 3256291B2 JP 25632792 A JP25632792 A JP 25632792A JP 25632792 A JP25632792 A JP 25632792A JP 3256291 B2 JP3256291 B2 JP 3256291B2
Authority
JP
Japan
Prior art keywords
present
norepinephrine
phenyl
compounds
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP25632792A
Other languages
English (en)
Japanese (ja)
Other versions
JPH05201961A (ja
Inventor
ドナルド・リチャード・ゲーラート
デイビッド・ウェイン・ロバートソン
デイビッド・タイワイ・ウォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH05201961A publication Critical patent/JPH05201961A/ja
Application granted granted Critical
Publication of JP3256291B2 publication Critical patent/JP3256291B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/29—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP25632792A 1991-09-27 1992-09-25 Ｎ−アルキル−３−フェニル−３−（２−アルキルチオフェノキシ）プロピルアミン類 Expired - Fee Related JP3256291B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/766,993 US5281624A (en) 1991-09-27 1991-09-27 N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US766993 1991-09-27

Publications (2)

Publication Number Publication Date
JPH05201961A JPH05201961A (ja) 1993-08-10
JP3256291B2 true JP3256291B2 (ja) 2002-02-12

Family

ID=25078150

Family Applications (2)

Application Number Title Priority Date Filing Date
JP25632792A Expired - Fee Related JP3256291B2 (ja) 1991-09-27 1992-09-25 Ｎ−アルキル−３−フェニル−３−（２−アルキルチオフェノキシ）プロピルアミン類
JP4256333A Withdrawn JPH05238996A (ja) 1991-09-27 1992-09-25 Ｎ−アルキル−３−フェニル−３−（２−ハロ置換フェノキシ）プロピルアミン類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP4256333A Withdrawn JPH05238996A (ja) 1991-09-27 1992-09-25 Ｎ−アルキル−３−フェニル−３−（２−ハロ置換フェノキシ）プロピルアミン類

Country Status (23)

Country Link
US (1) US5281624A (esLanguage)
EP (1) EP0534756A3 (esLanguage)
JP (2) JP3256291B2 (esLanguage)
KR (1) KR100221180B1 (esLanguage)
CN (1) CN1033580C (esLanguage)
AT (1) ATE124934T1 (esLanguage)
AU (1) AU655075B2 (esLanguage)
BR (2) BR9203743A (esLanguage)
CA (2) CA2079162A1 (esLanguage)
CZ (1) CZ281817B6 (esLanguage)
DE (1) DE69203424T2 (esLanguage)
FI (1) FI111250B (esLanguage)
HU (1) HU215519B (esLanguage)
IL (1) IL103277A (esLanguage)
MX (1) MX9205433A (esLanguage)
MY (1) MY108304A (esLanguage)
NO (1) NO178109C (esLanguage)
NZ (1) NZ244460A (esLanguage)
RU (1) RU2057120C1 (esLanguage)
SK (1) SK280480B6 (esLanguage)
TW (1) TW249225B (esLanguage)
YU (1) YU87192A (esLanguage)
ZA (1) ZA927240B (esLanguage)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US7087765B2 (en) * 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
KR19990035817A (ko) * 1995-07-24 1999-05-25 피터 지. 스트링거 주의력 결핍증/활동항진증의 치료 방법
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
AU756373B2 (en) * 1998-04-09 2003-01-09 Pharmacia & Upjohn Company New treatments for nervous disorders
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
NZ514612A (en) 1999-04-06 2004-01-30 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
DK1188747T3 (da) 1999-05-24 2006-01-23 Mitsubishi Pharma Corp Phenoxypropylaminforbindelser
PL196996B1 (pl) * 1999-07-01 2008-02-29 Upjohn Co Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
AU2002347984A1 (en) * 2001-11-30 2003-06-17 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
US20050009925A1 (en) * 2001-12-11 2005-01-13 Bymaster Franklin Porter Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
WO2004089288A2 (en) * 2003-04-04 2004-10-21 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
WO2005060949A2 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
ITMI20061987A1 (it) * 2006-10-16 2008-04-17 Archimica Srl Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
EP3697754A1 (en) * 2017-10-16 2020-08-26 Esteve Pharmaceuticals, S.A. Propanamine derivatives for treating pain and pain related conditions
CN113121394B (zh) * 2019-12-30 2022-11-08 中国药科大学 一种苯氧乙酸类衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4313896A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Aryloxyphenylpropylamines
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
CA1337128C (en) * 1988-04-08 1995-09-26 David Wayne Robertson Propanamine derivatives

Also Published As

Publication number Publication date
YU87192A (sh) 1995-10-24
DE69203424D1 (de) 1995-08-17
NO923710D0 (no) 1992-09-24
US5281624A (en) 1994-01-25
FI924305A0 (fi) 1992-09-25
CZ281817B6 (cs) 1997-02-12
KR930005972A (ko) 1993-04-20
TW249225B (esLanguage) 1995-06-11
CA2079161A1 (en) 1993-03-28
JPH05238996A (ja) 1993-09-17
NO178109C (no) 1996-01-24
RU2057120C1 (ru) 1996-03-27
AU2537092A (en) 1993-04-01
FI924305L (fi) 1993-03-28
SK290892A3 (en) 2000-02-14
CN1033580C (zh) 1996-12-18
HU9203051D0 (en) 1992-12-28
BR9203743A (pt) 1993-04-20
NO178109B (no) 1995-10-16
SK280480B6 (sk) 2000-02-14
CZ290892A3 (en) 1993-04-14
AU655075B2 (en) 1994-12-01
CA2079162A1 (en) 1993-03-28
NO923710L (no) 1993-03-29
HUT65375A (en) 1994-05-02
IL103277A0 (en) 1993-02-21
BR1100384A (pt) 1999-08-31
HU215519B (hu) 1999-01-28
CN1071416A (zh) 1993-04-28
NZ244460A (en) 1994-10-26
DE69203424T2 (de) 1996-01-11
MX9205433A (es) 1993-03-01
IL103277A (en) 1997-11-20
EP0534756A2 (en) 1993-03-31
MY108304A (en) 1996-09-30
ZA927240B (en) 1994-03-22
EP0534756A3 (en) 1993-06-16
FI111250B (fi) 2003-06-30
CA2079161C (en) 2004-02-17
KR100221180B1 (ko) 1999-09-15
ATE124934T1 (de) 1995-07-15
JPH05201961A (ja) 1993-08-10

Similar Documents

Publication Publication Date Title
JP3256291B2 (ja) Ｎ−アルキル−３−フェニル−３−（２−アルキルチオフェノキシ）プロピルアミン類
KR960003808B1 (ko) 3-아릴옥시-3-치환된 프로판아민, 이의 제조방법 및 이를 함유하는 약제학적 조성물
FI77018C (fi) Analogifoerfarande foer framstaellning av antidepressivt aktiv (-)-enantiomer av n-metyl-n-/3-(2-metylfenoxi) -3-fenylpropyl/amin och dess farmaceutiskt godtagbara salt.
DE68913930T2 (de) Serotonin- und Norepinephrin-Aufnahme-Inhibitoren.
CN116724023A (zh) 作为药物活性化合物的大麻素衍生物及其制备方法
DE69813896T2 (de) Alpha-aminoamidderivate die als analgetische mittel nützlich sind
EP0288188A1 (en) 1-Phenyl-3-naphthalenyloxy-propanamines
JPH0348679A (ja) テトラゾール系興奮性アミノ酸受容体アンタゴニスト
EP0369685B1 (en) Fluoxetine analog
JPH0317046A (ja) アリールオキシフエニルプロピルアミン、その製造方法及びその使用方法
EP0537915B1 (en) N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors
JPH02235A (ja) セロトニンおよびノルエピネフリン摂取阻害剤
EP0591581B1 (en) N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines
DE3879402T2 (de) Selektive sertonin-aufnahme-inhibitoren.
CA1198735A (en) Esters of 2-thenoylmercaptopropionylglycine with substituted hydroxybenzenes, process for their preparation and pharmaceutical compositions containing same
JP3681770B2 (ja) 老年性痴呆症又はアルツハイマー病治療剤
RU2266115C2 (ru) Оптически активные изомеры кетотифена и их терапевтически активные метаболиты
CN1099386A (zh) 1，2，5，6-四氢吡啶衍生物，其制备方法和它的治疗用途

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20011030

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees